Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pre-mRNA 3'-end-processing factor FIP1-like 1 (FIP1L1) is a protein-coding subunit of the cleavage and polyadenylation specificity factor (CPSF) complex, essential for polyadenylation and processing of mRNA 3'-ends in eukaryotic cells. FIP1L1 recognizes polyadenylation sites and binds U-rich RNA sequences, stimulating poly(A) polymerase activity to stabilize mRNAs for export and translation. In humans, a chromosomal deletion at 4q12 can create a fusion gene (FIP1L1-PDGFRA), resulting in a constitutively active tyrosine kinase driving hypereosinophilic syndrome and chronic eosinophilic leukemia. Imatinib and other kinase inhibitors target the fusion protein in affected patients. FIP1L1 is frequently studied for its role in RNA processing, leukemogenesis via gene fusion, and as a diagnostic, therapeutic, and prognostic marker in selected hematological malignancies.
Tyrosine kinase inhibition: Drugs like imatinib inhibit the constitutively active tyrosine kinase activity of the FIP1L1-PDGFRA fusion protein, leading to reduced proliferation of leukemia cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pre-mRNA 3'-end-processing factor FIP1-like 1 (FIP1L1).